Is tesamorelin FDA approved? Yes, for one specific use

Last updated 2026-07-25

Is tesamorelin FDA approved, and for what exactly?

Yes. Tesamorelin is an FDA-approved drug. It was approved under the brand name Egrifta in 2010, and a reformulated version, Egrifta SV, followed later. You can confirm the approval status yourself in Drugs@FDA, the agency's public database of approved drug products ^[1]. The approval is narrow. It covers exactly one indication: reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. That's it. The core evidence came from two multicenter, double-blind, placebo-controlled phase 3 trials, later pooled and published with safety extension data in the Journal of Clinical Endocrinology and Metabolism ^[2]. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), and multiple pharmacology reviews describe it that way, including a 2011 Nature Reviews Drug Discovery profile ^[3] and a 2009 Expert Opinion on Investigational Drugs review from before approval ^[4]. So the short answer is yes, it's approved, but the approval is indication-specific. It doesn't say anything about using tesamorelin for cosmetic fat loss in people without HIV, for muscle gain, or for slowing aging. Those uses exist in practice, but they sit outside what the FDA reviewed and cleared.

What is the FDA-approved indication for tesamorelin?

The approved indication is reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy, a fat redistribution syndrome tied to HIV infection and its treatment. Lipodystrophy in this context means visceral fat accumulation combined, often, with peripheral fat loss in the face, limbs, or buttocks ^[5]. Diagnosing that syndrome isn't simple. A 2012 review in Annales d'Endocrinologie on how to diagnose lipodystrophy syndromes notes that clinical exam plus imaging (CT or DEXA) is generally needed to confirm the fat redistribution pattern, since self-reported appearance change isn't a reliable diagnostic tool ^[6]. A 2022 review in the Journal of Clinical Endocrinology and Metabolism on approaching lipodystrophy patients covers the broader diagnostic workup clinicians use, including genetic and acquired forms beyond HIV-associated lipodystrophy ^[5]. This matters because the approval isn't for 'visceral fat' in the abstract. It's for visceral fat in a specific, diagnosable HIV-related condition. A person with ordinary abdominal fat and no HIV diagnosis doesn't fit the approved use case, even if the fat is in the same anatomical location.

What did the phase 3 trials actually show?

The pooled phase 3 analysis, published in 2010, combined two multicenter trials and included safety extension data ^[2]. The topline result driving approval was a measurable reduction in visceral adipose tissue on CT scan versus placebo, in HIV patients with excess abdominal fat. Follow-on analyses dug into specifics. A post hoc analysis published in the Journal of Clinical and Translational Science in 2023 looked at patients with and without dorsocervical fat pads (sometimes called "buffalo hump") and found tesamorelin's effect on VAT held regardless of that additional feature ^[7]. Separately, a 2011 study in AIDS examined inflammatory markers and found their reduction tracked with visceral fat loss, suggesting the metabolic benefit isn't just cosmetic but tied to reduced adipose-driven inflammation ^[8]. More recent randomized data extends the picture. A 2024 study in AIDS looked at tesamorelin's efficacy and safety specifically in people with HIV on modern integrase inhibitor regimens, a population that wasn't well represented in the original approval trials from over a decade earlier ^[9]. A 2026 meta-analysis of randomized controlled trials in Obesity Research & Clinical Practice pooled body composition, hepatic fat, metabolic, and safety outcomes across the tesamorelin RCT literature in HIV-associated lipodystrophy ^[10]. That's the closest thing to a consolidated efficacy picture across trials, and it's worth reading if you want the aggregate numbers rather than any single study.

Does the FDA approval mean tesamorelin is proven for general fat loss?

No. This is the single most important thing to get right about tesamorelin's approval status. The trials were run in HIV patients with a specific fat redistribution syndrome. Nothing in that dataset speaks to whether tesamorelin reduces fat in HIV-negative people, in people without lipodystrophy, or as a general weight-loss or body recomposition tool. Under FDA regulation, a drug's approved uses are defined by its labeling, and the "intended use" framework in 21 CFR 201.128 ties a product's regulatory status to how it's labeled and promoted, not to what a smaller offline population is using it for ^[11]. Off-label prescribing is legal and common in US medicine generally, but off-label use, by definition, isn't backed by the specific trial data that supported approval. Some mechanistic and secondary-outcome research has looked at other effects. A 2021 study in AIDS found tesamorelin improved fat quality (reducing fat density on CT, a marker linked to metabolic risk) independent of changes in fat quantity ^[12]. A 2025 study in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity ^[13]. These are legitimate research threads, but they are not FDA-reviewed indications. They're evidence in specific sub-populations, not a green light for broader use.

What other effects has tesamorelin shown in liver and metabolic studies?

The most-studied secondary benefit is on the liver. HIV-associated lipodystrophy overlaps heavily with non-alcoholic fatty liver disease (NAFLD), and several trials looked at whether reducing visceral fat with tesamorelin also improves liver fat and enzymes. A 2019 randomized, double-blind, multicenter trial in The Lancet HIV tested tesamorelin against placebo specifically for NAFLD in HIV patients and reported improvement in hepatic fat fraction ^[14]. A related 2017 study in AIDS connected visceral fat reduction with improved liver enzyme levels in the same population ^[15]. Mechanistic follow-up work has tried to explain why: a 2020 JCI Insight study examined tesamorelin's effects on hepatic transcriptomic signatures in HIV-associated NAFLD ^[16], and a 2021 Scientific Reports paper used targeted proteomics and transcriptomics to map out tesamorelin response pathways in the same condition ^[17]. None of this is an FDA-approved indication either. Fatty liver improvement is a secondary or exploratory outcome in HIV lipodystrophy trials, not a separate approval. If your primary interest is liver fat rather than visceral adipose tissue specifically, that distinction matters when you're weighing evidence.

What are the approved dosing and administration details?

Tesamorelin is given as a once-daily subcutaneous injection. Population pharmacokinetic work published in Clinical Pharmacokinetics in 2015 modeled tesamorelin exposure across HIV-infected patients and healthy subjects, supporting the dosing approach used in later trials and label guidance ^[18]. This article isn't a dosing guide. If you're looking for injection mechanics, timing, or how to handle reconstitution, those are separate, detailed topics: see how to reconstitute tesamorelin, tesamorelin how to inject, and best time to take tesamorelin peptide for the practical side. Injection site rotation and technique also have their own considerations, covered in tesamorelin injection sites. One dosing-adjacent point worth flagging here: because the approval is for a specific patient population studied over specific trial durations, questions about how long to run tesamorelin, when to expect visible change, or whether cycling makes sense go beyond what the approval label settles. See tesamorelin cycle length for that discussion.

What are the known side effects and safety concerns?

Tesamorelin's safety data comes mainly from the same phase 3 program that supported approval, plus the safety extension data pooled into the 2010 analysis ^[2]. Reviews summarizing that safety profile, including a 2011 Drugs journal review ^[19] and a 2012 Annals of Pharmacotherapy review ^[20], describe injection site reactions, joint-related symptoms (arthralgia), and peripheral edema as the more commonly reported issues, consistent with the drug's mechanism of raising growth hormone and IGF-1. Because tesamorelin works upstream, stimulating the pituitary to release the body's own GH rather than delivering GH directly, it carries theoretical concerns common to the GHRH/GH axis: fluid retention, potential effects on glucose metabolism, and the general caution around stimulating GH pathways in anyone with a history of certain cancers. A 2013 review in Best Practice & Research Clinical Endocrinology & Metabolism on growth hormone in the aging male discusses these class-wide GH-axis concerns, though it isn't tesamorelin-specific ^[21]. A 2026 meta-analysis in Obesity Research & Clinical Practice pooled safety outcomes across tesamorelin RCTs in HIV lipodystrophy alongside efficacy data, giving a more consolidated view of adverse event rates than any single trial ^[10]. If you want the full safety discussion including contraindications and monitoring, that belongs on a dedicated safety page rather than here; this article's job is the approval status question.

Why is tesamorelin used off-label, and is that legal?

Off-label prescribing (a doctor prescribing an approved drug for a use, population, or dose not on the label) is legal in US medicine and happens across many drug classes, more than peptides. What changes with tesamorelin is where the drug comes from and how it's regulated when used outside the approved product. The FDA-approved product is Egrifta / Egrifta SV, manufactured by the brand holder and dispensed under that approval. Separately, tesamorelin acetate as a raw material has its own compounding regulatory pathway. Compounded versions fall under 21 U.S.C. 353a, the federal statute governing pharmacy compounding ^[22], and bulk drug substances used in 503A compounding are governed by FDA's bulks list process, laid out in 21 CFR 216.23 ^[23] and the related 503B outsourcing facility bulks list in 21 CFR 216.24 ^[24]. FDA maintains guidance specifically on bulk drug substances used in compounding under section 503A ^[25]. This distinction is why you'll see tesamorelin available both as the branded, FDA-approved injectable and as a compounded product from a licensed pharmacy. They are not regulated identically, and the compounded route doesn't carry the same FDA product-specific review. If you're comparing sourcing options, tesamorelin cost walks through how pricing differs between the branded product and compounded alternatives.

How does tesamorelin's approval compare to other GH-related peptides?

Tesamorelin sits in a small category: it's one of the few GHRH-axis peptides with a full FDA approval and phase 3 trial data behind a specific indication. Most other peptides marketed in the same general space (various GHRH analogues, GH secretagogues, and related research compounds) don't have that. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews covers therapeutic peptides in orthopaedics generally, noting the gap between compounds with real regulatory approval and the larger pool of peptides used off-label or in research settings ^[26]. A companion 2026 primer in The American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians, makes a similar point about injectable peptide therapy broadly: approval status varies enormously across the peptide landscape, and clinicians need to check that status compound by compound rather than assuming a class-wide standard ^[27]. A 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws the same line explicitly ^[28]. Here's the practical table: | Compound category | FDA approval status | Phase 3 RCT data | Approved indication |

Can tesamorelin be detected in doping or anti-doping testing?

Yes, and this is relevant if you're an athlete subject to testing. Tesamorelin is a synthetic GHRH analogue, and GHRH analogues as a class are on doping control radar because they stimulate endogenous GH release, which can mask as "natural" GH on standard panels. A 2021 review in Drug Testing and Analysis covers advances in detecting GHRH synthetic analogs, describing the analytical methods anti-doping labs use to distinguish synthetic GHRH peptides like tesamorelin from the body's own hormones ^[29]. If you're competing under a testing body's rules, assume tesamorelin is covered by prohibited substance lists targeting GH-releasing peptides, and confirm directly with your sport's anti-doping authority before use. This isn't a gray area worth guessing on.

Where does the provider-reviewed route fit in?

Given the narrow approval and the off-label reality for most people interested in tesamorelin outside HIV lipodystrophy, the decision that matters most isn't whether the drug "works", it's whether you're getting it through a route with real medical oversight. Tesamorelin Co is an editorial resource, not a pharmacy and not a compounder. We don't manufacture or dispense anything. What we can tell you plainly: the responsible path is a provider-reviewed process where a licensed clinician assesses your history, discusses on-label versus off-label context honestly, and, if appropriate, routes the prescription to a fulfilling pharmacy partner operating under the compounding rules described above ^[22][23]. Skipping that oversight, buying from unregulated "research chemical" sellers, removes the safety net that even off-label use should have. If cost is the main barrier to going the provider-reviewed route, tesamorelin cost breaks down what branded versus compounded pricing actually looks like, which is often the deciding factor in practice.

Frequently asked questions

Is tesamorelin FDA approved for weight loss?

No. Tesamorelin is FDA approved only for reducing excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[2]. It is not approved as a general weight-loss drug, and no phase 3 trial data supports that broader use.

What is the brand name of FDA-approved tesamorelin?

The FDA-approved product is Egrifta, approved in 2010, with a reformulated version called Egrifta SV following later. You can verify current approval status directly in the FDA's Drugs@FDA database ^[1].

Is tesamorelin approved for people without HIV?

No. The approval covers HIV-infected patients with lipodystrophy specifically. Use in HIV-negative individuals, for any purpose, is off-label and not supported by the core phase 3 trial data ^[2].

What condition does FDA-approved tesamorelin treat?

It treats excess visceral abdominal fat caused by HIV-associated lipodystrophy, a fat redistribution syndrome linked to HIV infection and its treatment ^[5]. Diagnosis typically requires clinical exam plus imaging, more than visible body changes ^[6].

Does tesamorelin's approval cover anti-aging use?

No. There is no FDA-approved anti-aging indication for tesamorelin. Any anti-aging or general body composition use is off-label, and the evidence base cited for approval doesn't address non-HIV populations ^[2][11].

Is compounded tesamorelin the same as FDA-approved tesamorelin?

It's the same molecule but not the same regulated product. The FDA-approved brand goes through full product review; compounded tesamorelin is made under separate compounding law (21 U.S.C. 353a) and FDA's bulk drug substance rules ^[22][23].

What side effects were reported in tesamorelin's approval trials?

Reviews of the phase 3 program report injection site reactions, joint pain (arthralgia), and peripheral edema as the more commonly noted side effects ^[19][20]. These align with expected effects of raising growth hormone and IGF-1 levels.

Does tesamorelin help with fatty liver disease?

In HIV patients with NAFLD, a 2019 randomized trial in The Lancet HIV found tesamorelin improved hepatic fat fraction versus placebo ^[14]. This is a studied secondary benefit within the HIV lipodystrophy population, not a separate FDA-approved indication.

Can tesamorelin be detected in drug testing for athletes?

Yes. As a synthetic GHRH analogue, tesamorelin can be distinguished from natural GH using specialized anti-doping analytical methods, per a 2021 review in Drug Testing and Analysis ^[29]. Athletes subject to testing should check their sport's prohibited list directly.

How was tesamorelin's FDA approval supported by evidence?

Approval rested on two multicenter, double-blind, placebo-controlled phase 3 trials, pooled and published with safety extension data in 2010, showing reduced visceral adipose tissue in HIV patients with excess abdominal fat versus placebo ^[2].

Is off-label tesamorelin use legal?

Yes, off-label prescribing is legal in US medicine generally. It means using an approved drug outside its FDA-reviewed indication, which is common across many drug classes, but it means the specific approval trial data doesn't cover that use ^[11][22].

Has tesamorelin been studied in people on modern HIV medications?

Yes. A 2024 study in AIDS specifically evaluated tesamorelin's efficacy and safety in people with HIV on integrase inhibitor regimens, a more current treatment context than the original approval-era trials ^[9].

Sources

1. FDA, Drugs@FDA database: Tesamorelin (Egrifta) approval status can be verified directly in FDA's public drug approval database
2. J Clin Endocrinol Metab, 2010 (PMID 20554713): Pooled analysis of two phase 3 double-blind placebo-controlled trials with safety extension data supported tesamorelin's approval for reducing visceral fat in HIV lipodystrophy
3. Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin is characterized as a synthetic GHRH analogue
4. Expert Opin Investig Drugs, 2009 (PMID 19243281): Pre-approval review describing tesamorelin as a human growth hormone releasing factor analogue
5. J Clin Endocrinol Metab, 2022 (PMID 35137140): Approach to diagnosing lipodystrophy syndromes, including HIV-associated fat redistribution
6. Annales d'Endocrinologie, 2012 (PMID 22748602): Diagnosing lipodystrophy syndrome typically requires clinical exam plus imaging rather than visible change alone
7. J Clin Transl Sci, 2023 (PMID 36845310): Post hoc analysis found tesamorelin's visceral fat effect held regardless of dorsocervical fat pad presence
8. AIDS, 2011 (PMID 21516030): Reduction in inflammatory markers with tesamorelin tracked with visceral adipose tissue reduction
9. AIDS, 2024 (PMID 38905488): Efficacy and safety of tesamorelin evaluated specifically in people with HIV on integrase inhibitor regimens
10. Obesity Res Clin Pract, 2026 (PMID 41545261): Meta-analysis of RCTs pooled body composition, hepatic fat, metabolic and safety outcomes for tesamorelin in HIV-associated lipodystrophy
11. eCFR, 21 CFR 201.128: Federal regulation defines a drug's intended use based on labeling and promotion, framing why off-label use isn't covered by an approval
12. AIDS, 2021 (PMID 33756511): Tesamorelin improved fat quality (density) independent of changes in fat quantity
13. J Infect Dis, 2025 (PMID 39813152): Study examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity
14. Lancet HIV, 2019 (PMID 31611038): Randomized double-blind multicenter trial found tesamorelin improved hepatic fat fraction in HIV-associated NAFLD
15. AIDS, 2017 (PMID 28832410): Visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients
16. JCI Insight, 2020 (PMID 32701508): Study examined tesamorelin's effects on hepatic transcriptomic signatures in HIV-associated NAFLD
17. Scientific Reports, 2021 (PMID 34006921): Targeted proteomic and transcriptomic approach mapped tesamorelin response pathways in HIV-associated NAFLD
18. Clin Pharmacokinet, 2015 (PMID 25358450): Population pharmacokinetic analysis modeled tesamorelin exposure in HIV-infected patients and healthy subjects
19. Drugs, 2011 (PMID 21668043): Review of tesamorelin's use in HIV-associated lipodystrophy summarizing safety profile
20. Annals of Pharmacotherapy, 2012 (PMID 22298602): Review describing tesamorelin's adverse effect profile including injection site reactions and edema
21. Best Pract Res Clin Endocrinol Metab, 2013 (PMID 24054930): Discussion of growth hormone axis concerns including fluid retention and glucose metabolism effects relevant to GH-stimulating therapies
22. Cornell Law, 21 U.S.C. 353a: Federal statute governing pharmacy compounding, applicable to compounded tesamorelin products
23. eCFR, 21 CFR 216.23 (503A Bulks List): Regulation governing which bulk drug substances, including tesamorelin acetate, may be used in 503A pharmacy compounding
24. eCFR, 21 CFR 216.24 (503B Bulks List): Parallel regulation governing bulk drug substances for 503B outsourcing facility compounding
25. FDA, bulk drug substances used in compounding under section 503A: FDA guidance describes the process for bulk drug substances, including tesamorelin, used in 503A compounding
26. JAAOS Global Res Rev, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics notes the gap between FDA-approved compounds and off-label/research peptides
27. Am J Sports Med, 2026 (PMID 41476424): Primer for sports medicine physicians on injectable peptide therapy stresses checking approval status compound by compound
28. Sports Medicine, 2026 (PMID 41966639): Review distinguishes approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance
29. Drug Testing and Analysis, 2021 (PMID 34665524): Review covers analytical methods for detecting synthetic GHRH analogues like tesamorelin in anti-doping testing